Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early stage breast cancer (NCT01372579) von Kaklamani, Virginia G., Hughes, Elisha, Siziopikou, Kalliopi P., Timms, Kirsten, Abkevich, Victor, Solimeno, Cara, Hartman, Anne-Renee, Jeruss, Jacqueline, Meservey, Caitlin, Jovanovic, Borko, Helenowski, Irene B., Kahn, Seema, Bethke, Kevin P., Hansen, Nora, Uthe, Regina, Rosen, Steven, Hoskins, Kent, Von Roenn, Jamie, Jain, Sarika, Gradishar, William John

Volltext

Incidence and Etiology of Potentially Preventable ICU Readmissions von Al-Jaghbeer, Mohammed J., Tekwani, Seema S., Gunn, Scott R., Kahn, Jeremy M.

Volltext

777: INCIDENCE AND ETIOLOGY OF POTENTIALLY PREVENTABLE ICU READMISSIONS von Al-Jaghbeer, Mohammed, Tekwani, Seema, Kahn, Jeremy, Gunn, Scott

Volltext

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants von Lyke, Kirsten E., Atmar, Robert L., Dominguez Islas, Clara, Posavad, Christine M., Deming, Meagan E., Branche, Angela R., Johnston, Christine, El Sahly, Hana M., Edupuganti, Srilatha, Mulligan, Mark J., Jackson, Lisa A., Rupp, Richard E., Rostad, Christina A., Coler, Rhea N., Bäcker, Martín, Kottkamp, Angelica C., Babu, Tara M., Dobrzynski, David, Martin, Judith M., Brady, Rebecca C., Frenck, Robert W., Rajakumar, Kumaravel, Kotloff, Karen, Rouphael, Nadine, Szydlo, Daniel, PaulChoudhury, Rahul, Archer, Janet I., Crandon, Sonja, Ingersoll, Brian, Eaton, Amanda, Brown, Elizabeth R., McElrath, M. Juliana, Neuzil, Kathleen M., Stephens, David S., Post, Diane J., Lin, Bob C., Serebryannyy, Leonid, Beigel, John H., Montefiori, David C., Roberts, Paul C.

Volltext

Association of SDF1 inhibition with local control and relative cerebral blood volume of glioblastoma von Thomas, Reena Parada, Nagpal, Seema, Iv, Michael, Soltys, Scott G., Recht, Cathy Kahn, Bertrand, Sophie, Makar, Sherif Mark, Corbin, Zachary, Mandic, Kseniya, Coffey, Gwen, Pelpola, Shanika, Prado, Isabel P, Brown, Martin, Recht, Lawrence David

Volltext

Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma von Nagpal, Seema, Recht, Cathy Kahn, Bertrand, Sophie, Thomas, Reena Parada, Ajlan, Abdulrazag, Pena, Justine, Gershon, Megan, Coffey, Gwen, Kunz, Pamela L., Li, Gordon, Recht, Lawrence D.

Volltext

A phase I study of chemo-radiotherapy with plerixafor for newly diagnosed glioblastoma (GB) von Thomas, Reena Parada, Nagpal, Seema, Iv, Michael, Soltys, Scott G., Corbin, Zachary, Xu, Linda Wei, Recht, Cathy Kahn, Bertrand, Sophie, Jain, Vani, Acevedo, Brenda, Brown, Martin, Recht, Lawrence David

Volltext

Etirinotecan pegol (EP, NKTR-102) in the treatment of high-grade glioma (HGG): A phase 2 trial von Nagpal, Seema, Recht, Cathy Kahn, Imtiaz, Urooj, Bertrand, Sophie, Thomas, Reena Parada, Ajlan, Abdulrazag, Pena, Justine, Gershon, Megan, Kunz, Pamela L., Li, Gordon, Recht, Lawrence David

Volltext